On the stock market since 2016, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 37% a year on average.
Sales run at $6.7M a year. A small number, but proof the product has real buyers.
A loss of $385K against $6.7M in annual sales.
The stock sits at $0.0000. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.2 years. After that, the company needs to find new money.
On our five-subject report card, NAVA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NAVA is a high-risk stock — not yet profitable, and its future rides on its product catching on.